INJECTION SITE LYMPHADENOPATHY

INJECTION SITE LYMPHADENOPATHY was reported 23 times

INJECTION SITE LYMPHADENOPATHY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Phenylalanine Metabolizing Enzyme [EPC] 2 0.0002
1 Interleukin-17A Antagonist [EPC] 1 0.0000
2 Anti-IgE [EPC] 2 0.0000
3 Histamine-1 Receptor Antagonist [EPC] 1 0.0000
4 Acetylcholine Release Inhibitor [EPC] 1 0.0000
5 Sulfonylurea [EPC] 1 0.0000
6 Interleukin-4 Receptor alpha Antagonist [EPC] 3 0.0000
7 HMG-CoA Reductase Inhibitor [EPC] 1 0.0000
8 Vitamin C [EPC] 1 0.0000
9 Tumor Necrosis Factor Blocker [EPC] 1 0.0000
10 Nonsteroidal Anti-inflammatory Drug [EPC] 1 0.0000